Focuses on developing and commercializing differentiated products for the treatment of chronic conditions.
Avadel Pharmaceuticals plc is a prominent biopharmaceutical company based in Dublin, Ireland, with a strong presence in the United States. The company is dedicated to advancing innovative treatments that address significant medical needs. Avadel's primary focus is on FT218, its lead product candidate. FT218 is a formulation of sodium oxybate currently undergoing Phase 3 clinical trials for the treatment of excessive daytime sleepiness and cataplexy in adults suffering from narcolepsy, aiming to provide effective management and improved quality of life for patients.
Originally known as Flamel Technologies SA, the company underwent a name change to Avadel Pharmaceuticals plc in January 2017, marking a strategic shift in its corporate identity and focus on pharmaceutical development. Founded in 2015, Avadel Pharmaceuticals has quickly established itself as a leader in sleep disorder treatments, leveraging its scientific expertise and innovative approach to drug formulation.
Headquartered in Dublin, Avadel Pharmaceuticals plc operates at the forefront of biopharmaceutical innovation, driven by a commitment to improving patient outcomes through cutting-edge research and development. With a robust pipeline and a dedicated team of professionals, the company continues to expand its capabilities and pursue novel therapeutic solutions to address unmet medical needs globally.